S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
US Dollar Replaced By "Biden Bucks"? (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
US Dollar Replaced By "Biden Bucks"? (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
US Dollar Replaced By "Biden Bucks"? (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
US Dollar Replaced By "Biden Bucks"? (Ad)
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
US Dollar Replaced By "Biden Bucks"? (Ad)
LON:NCYT

Novacyt - NCYT Share Forecast, Price & News

GBX 116.22
-0.83 (-0.71%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
115.22
118.30
50-Day Range
106.68
175
52-Week Range
104.73
497.30
Volume
73,910 shs
Average Volume
355,980 shs
Market Capitalization
£82.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 570

Novacyt MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
390.4% Upside
GBX 570 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Novacyt in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
£819,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

NCYT stock logo

About Novacyt (LON:NCYT) Stock

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

Novacyt Stock Performance

NCYT traded down GBX 0.33 ($0.00) during trading on Thursday, hitting GBX 116.72 ($1.41). The stock had a trading volume of 58,242 shares, compared to its average volume of 355,862. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.74 and a current ratio of 4.08. The firm has a market capitalization of £82.43 million and a P/E ratio of -8.30. The company's 50-day moving average price is GBX 132.49 and its 200 day moving average price is GBX 166.27. Novacyt has a twelve month low of GBX 104.73 ($1.27) and a twelve month high of GBX 497.30 ($6.01).

Insider Buying and Selling

In related news, insider James Wakefield bought 7,000 shares of the firm's stock in a transaction that occurred on Thursday, July 7th. The shares were acquired at an average cost of GBX 117 ($1.41) per share, with a total value of £8,190 ($9,896.09).

Receive NCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter.

NCYT Stock News Headlines

Novacyt S.A.: Launch of Monkeypox Assay
See More Headlines
Receive NCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 570
High Stock Price Forecast
GBX 570
Low Stock Price Forecast
GBX 570
Forecasted Upside/Downside
+390.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£95.78 million
Cash Flow
GBX 141.93 per share
Book Value
GBX 200.80 per share

Miscellaneous

Free Float
N/A
Market Cap
£82.09 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. David James Allmond (Age 52)
    CEO & Director
  • Mr. James Martin McCarthy (Age 56)
    CFO & Director
  • Bryan Close
    Chief Operations Officer
  • Ms. Wendy Karban
    Group HR Mang.
  • Mr. David Franks
    Chief HR Officer
  • Paul Oladimeji
    Group Head of R&D
  • Mr. Gérald Ulrich
    Chief Exec. Officer of Bus. Devel.
  • Mr. Steve Gibson
    Group Financial Controller













NCYT Stock - Frequently Asked Questions

Should I buy or sell Novacyt stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novacyt in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NCYT shares.
View NCYT analyst ratings
or view top-rated stocks.

What is Novacyt's stock price forecast for 2022?

1 equities research analysts have issued twelve-month price targets for Novacyt's shares. Their NCYT share price forecasts range from GBX 570 to GBX 570. On average, they predict the company's share price to reach GBX 570 in the next year. This suggests a possible upside of 390.4% from the stock's current price.
View analysts price targets for NCYT
or view top-rated stocks among Wall Street analysts.

How have NCYT shares performed in 2022?

Novacyt's stock was trading at GBX 369.45 at the beginning of 2022. Since then, NCYT stock has decreased by 68.5% and is now trading at GBX 116.23.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Novacyt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novacyt investors own include Biocept (BIOC), Ecolab (ECL), genedrive (GDR), Geron (GERN), Immunic (IMUX), Tiziana Life Sciences (TILS), Verastem (VSTM), VYNE Therapeutics (VYNE), Antero Midstream (AM) and Aileron Therapeutics (ALRN).

What is Novacyt's stock symbol?

Novacyt trades on the London Stock Exchange (LON) under the ticker symbol "NCYT."

How do I buy shares of Novacyt?

Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Novacyt's stock price today?

One share of NCYT stock can currently be purchased for approximately GBX 116.23.

How much money does Novacyt make?

Novacyt (LON:NCYT) has a market capitalization of £82.09 million and generates £95.78 million in revenue each year.

How many employees does Novacyt have?

The company employs 174 workers across the globe.

How can I contact Novacyt?

The official website for the company is www.novacyt.com. The company can be reached via phone at 33 1 39 46 51 04.

This page (LON:NCYT) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.